CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Glycemic control accounts for less than 20% of cardiovascular event reduction with incretin therapies, indicating other mechanisms are significant.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpusSummary and findings
This review discusses the cardiovascular effects of incretin-based therapies, including retatrutide, focusing on mechanisms beyond glycemic control. It highlights that glycemic improvement contributes to less than 20% of the reduction in major adverse cardiovascular events. The review also notes direct positive inotropic effects of retatrutide in isolated human atrial preparations.
Abstract
Incretin-based therapies have evolved from selective GLP-1RA to dual GLP-1/ GIP agonists and unimolecular triple GLP-1/GIP/glucagon receptor agonists. This review examines the cardiovascular effects of these three pharmacological tiers, with emphasis on mechanisms that operate beyond glycaemic control. Mediation analyses of major CVOTs indicate that glycaemic improvement accounts for less than 15 to 20 percent of the reduction in major adverse cardiovascular events achieved by these agents. The remainder reflects converging effects on weight reduction, lipid remodelling, blood pressure, systemic inflammation, and direct myocardial protection. At the cellular level, incretin signalling preserves mitochondrial bioenergetics, activates antioxidant defences, and inhibits multiple cardiomyocyte death pathways. At the tissue level, recent investigations in isolated human atrial preparations demonstrate direct positive inotropic effects of both GLP-1RA and the triple agonist retatrutide. Cardiac magnetic resonance evidence from the SUMMIT programme documents reverse left ventricular remodelling with tirzepatide in obesity-related heart failure with preserved ejection fraction. Phase 2 data for triple agonists have produced unprecedented surrogate cardiovascular improvements, while Phase 3 outcome data from the TRIUMPH programme remain awaited. The cardiovascular pharmacology of metabolic disease has been fundamentally reshaped, and ongoing trials will determine whether multi-receptor agonism establishes a new therapeutic standard.
Background
This review addresses the cardiovascular effects of incretin receptor agonists, which have evolved from selective GLP-1 receptor agonists to more complex multi-receptor agonists. Previous studies have established the role of glycemic control in cardiovascular outcomes, but this review emphasizes that other factors may play a significant role. Understanding these mechanisms is crucial as it may influence future therapeutic strategies in managing cardiovascular risks associated with metabolic diseases.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
The findings suggest that while glycemic control is important, it is not the sole contributor to cardiovascular benefits seen with incretin therapies. The review indicates that mechanisms such as weight reduction and direct myocardial protection may be significant, but the clinical relevance of these findings remains to be fully established. Limitations include reliance on data from other studies and the absence of original research data in this review.
Key findings
- Glycaemic improvement accounts for less than 15 to 20 percent of the reduction in major adverse cardiovascular events.
- Phase 2 data for triple agonists have produced unprecedented surrogate cardiovascular improvements.
- Cardiac magnetic resonance evidence from the SUMMIT programme documents reverse left ventricular remodelling with tirzepatide in obesity-related heart failure with preserved ejection fraction.
Limitations
- Not a primary research study; relies on data from other studies.
- Does not report specific sample sizes or statistical analyses.
- Focuses on surrogate endpoints rather than direct clinical outcomes.